Mometasone furoate 0.1%

Mometasone binds glucocorticoid receptors with high affinity and suppresses the NF-κB-driven cytokine cascade that sustains eczema inflammation. Its once-daily efficacy is explained by its skin pharmacokinetics: it has a long residence time in the epidermis and dermis, maintaining anti-inflammatory activity for roughly 24 hours after a single application — unlike some other mid-potency agents where receptor-active concentrations fall below therapeutic levels sooner.

The ointment formulation is more occlusive than the cream, which increases penetration and effective potency per application. That makes ointment the right vehicle for thicker, more treatment-resistant patches, while cream is the default starting vehicle for acute, inflamed skin.

Mometasone furoate 0.1% has extensive RCT evidence for atopic dermatitis in both adults and children. Multiple trials confirm once-daily mometasone is non-inferior to twice-daily regimens of comparable mid-potency agents, directly supporting the simplified dosing recommendation. Cochrane reviews of topical corticosteroids consistently include mometasone as one of the better-evidenced compounds in its class.

It appears in AAD, EADV (European Academy of Dermatology), and British Association of Dermatology guidelines as a standard option for moderate atopic dermatitis, and there is dedicated pediatric trial data confirming the once-daily dosing recommendation was validated in children rather than extrapolated from adult studies.

Not for the face, neck, groin, underarms, or other skin folds. Mometasone’s position toward the stronger end of the mid-potency range means it carries slightly more atrophy risk than triamcinolone or fluticasone, and thin-skinned areas won’t tolerate it well. Not for skin that’s actively infected — the immunosuppressive effect can let a bacterial or viral infection spread.

Not for continuous, uninterrupted daily use over months. Once-daily dosing is an advantage for adherence, but it can create a false sense that “one application is always fine” — applying a large amount over large surface areas daily for months is still problematic. Tell your clinician if you have a history of Cushing’s syndrome, diabetes, or elevated intracranial pressure before starting.